Pharmidex Part of Consortium in New Innovate UK Grant
December 11, 2019

A Consortium led by Intract Pharma has successfully been awarded funding from Innovate UK to develop a scalable manufacturing process for novel oral antibody products using it's proprietary Soteria® technology. Pharmidex are also members of this consortium together with Centre for Process Innovation (CPI) and Quay Pharma.

Intract Pharma Ltd has successfully been awarded funding from Innovate UK, the UK’s innovation agency, to develop a scalable manufacturing process for novel oral antibody products using its proprietary Soteria® technology. The collaborative industrial research project, totalling over £1.4 million, was secured through the Industrial Strategy Challenge Fund for innovative projects in medicines manufacturing. This program will be conducted by a consortium led by Intract, including the Centre for Process Innovation (CPI), Pharmidex and Quay Pharma.


Each member of the consortium brings unique expertise in drug development and manufacture, with an extensive understanding of pharmaceutical formulation. The project seeks to develop a manufacturing process for Intract’s revolutionary Soteria® technology which can be scaled in a commercially viable manner. Soteria® transforms painful and inconvenient injectable therapies into safe, simple oral formulations, and allows targeting and concentration of the antibody at the site of disease in the gut to improve therapeutic efficacy whilst minimising risk of systemic toxicity.


About Pharmidex


Pharmidex provides translational solutions using its world-renowned expertise in CNS/Oncology, drug discovery and ADMET/PK. Founded in the UK in 2002, Pharmidex operates in state-of-the-art facilities in London and Hatfield to provide high quality bespoke experimental data to support drug discovery & development.


About Intract Pharma


Intract Pharma is an oral drug delivery specialist, developing state-of-the-art formulation technologies and unique gastrointestinal models to develop advanced new therapeutics. Since its inception, Intract has pursued innovation in oral drug delivery as a means to improve on current therapies, making them safer and more effective for patients. Soteria® is available for license exclusively from Intract Pharma. For more information visit www.intractpharma.com


About CPI


The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult. The company uses applied knowledge in science and engineering combined with state-of-the-art development facilities to enable its clients to develop, prove, prototype and scale up the next generation of products and processes. Its open innovation model enables clients to develop products and prove processes with minimal risk. CPI provides assets and expertise, so customers can demonstrate processes before investing substantial amounts of money in capital equipment and training. New products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale. By utilising its proven assets and expertise, companies can take their products and processes to market faster. There is no down time in production as all of the process development is completed offsite and CPI’s technology transfer and engineering teams can help companies transfer the product or process into full-scale production at speed.


About Quay Pharma


Quay Pharmaceuticals is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials manufacturing for pharmaceutical and biotechnology companies worldwide. Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre-clinical through to the end of phase II clinical trials. Quay Pharmaceuticals has built a reputation for specialising in the formulation of APIs that exhibit poor solubility and bio-availability and those which require modified or controlled release.


About Innovate UK


Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org

? Pharmidex is proud to sponsor CamMedChem’25! ?
September 12, 2025
We’re delighted to announce that Pharmidex will be an official sponsor of CamMedChem’25 , the renowned meeting organized by the Royal Society of Chemistry’s Biomolecular Chemistry Special Interest Group This year’s theme promises cutting-edge discussions in medicinal chemistry, biomolecular interactions and the latest trends in small molecule and chemical biology research. We’re honoured to support such a pivotal forum for scientists, drug discovery experts and academic innovators to exchange ideas, foster collaborations, and advance therapeutic discovery. 👉 We look forward to: Learning from the powerful scientific insights shared at the meeting Exploring new partnerships that further the translation of biomolecular science into impactful therapies We can’t wait to see you in Cambridge for CamMedChem’25!
Pharmidex Histology Services: Precision You Can Trust
September 8, 2025
At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology
? Expanding our integrated capabilities in autoimmune research
September 3, 2025
At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.
More Posts